Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.

Steppan I, Reimer D, Sevelda U, Ulmer H, Marth C, Zeimet AG.

Chemotherapy. 2009;55(6):391-8. doi: 10.1159/000262452. Epub 2009 Nov 30.

PMID:
19955744
2.

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.

Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK.

Gynecol Oncol. 2009 Aug;114(2):219-24. doi: 10.1016/j.ygyno.2009.04.007. Epub 2009 May 17.

PMID:
19446868
3.

Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.

Strauss HG, Hemsen A, Karbe I, Lautenschl├Ąger C, Persing M, Thomssen C.

Anticancer Drugs. 2008 Jun;19(5):541-5. doi: 10.1097/CAD.0b013e3282fcbbf7.

PMID:
18418221
4.

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO).

Anticancer Res. 2008 Mar-Apr;28(2B):1329-34.

5.

Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.

Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schl├╝ter C, Oskay-Ozcelik G; North-Eastern German Society of Gynecological Oncology.

Cancer Chemother Pharmacol. 2009 Aug;64(3):585-91. doi: 10.1007/s00280-008-0909-1. Epub 2009 Jan 21.

PMID:
19156414
6.

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.

Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.

Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72.

PMID:
10985896
7.

Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.

Gordinier ME, Dizon DS, Fleming EL, Weitzen S, Schwartz J, Parker LP, Granai CO.

Gynecol Oncol. 2006 Oct;103(1):72-4. Epub 2006 Feb 21.

PMID:
16494932
8.

Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.

Taiwanese Gynecologic Oncology Group, Chou HH, Wang KL, Chen CA, Wei LH, Lai CH, Hsieh CY, Yang YC, Twu NF, Chang TC, Yen MS.

Gynecol Oncol. 2006 Jun;101(3):423-8. Epub 2005 Dec 1.

PMID:
16325239
9.

Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.

Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ.

Gynecol Oncol. 2007 Aug;106(2):375-80. Epub 2007 May 18.

PMID:
17512575
10.

Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.

Dear RF, Gao B, Harnett P.

Asia Pac J Clin Oncol. 2010 Mar;6(1):66-73. doi: 10.1111/j.1743-7563.2009.01263.x.

PMID:
20398040
11.

Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.

Gorumlu G, Kucukzeybek Y, Kemal-Gul M, Karaca B, Cosan-Terek M, Karabulut B, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Uslu R.

J BUON. 2008 Jul-Sep;13(3):349-52.

PMID:
18979548
12.

Effectiveness of a nursing support program for patients with recurrent ovarian cancer receiving pegylated liposomal doxorubicin (Caelyx/Doxil).

Grenier N, Lebel V, Gill M, Mullen T, Mitchinson K, Sebborn K, Pouliot JF.

Can Oncol Nurs J. 2007 Summer;17(3):133-40. English, French.

PMID:
17944313
13.

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P.

J Clin Oncol. 2012 Nov 1;30(31):3841-7. doi: 10.1200/JCO.2011.38.8082. Epub 2012 Sep 17.

PMID:
22987083
14.

Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.

Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K.

Jpn J Clin Oncol. 2008 Nov;38(11):777-85. doi: 10.1093/jjco/hyn101. Epub 2008 Oct 16.

15.

Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.

Miolo G, Baldo P, Bidoli E, Lombardi D, Scalone S, Sorio R, Veronesi A.

Tumori. 2009 Nov-Dec;95(6):687-90.

16.

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.

Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ.

Gynecol Oncol. 2006 Oct;103(1):212-8. Epub 2006 May 3.

PMID:
16677696
17.

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G.

J Clin Oncol. 2008 Feb 20;26(6):890-6. doi: 10.1200/JCO.2007.13.6606.

PMID:
18281662
18.

Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment.

Tanguay JS, Ansari J, Buckley L, Fernando I.

Int J Gynecol Cancer. 2009 Apr;19(3):361-6. doi: 10.1111/IGC.0b013e3181a1c7aa.

PMID:
19407560
19.

A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer.

Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, Carta G, Necozione S, Mantovani G, Rea S.

Gynecol Oncol. 2007 Jul;106(1):164-9. Epub 2007 May 3.

PMID:
17481704
20.

Supplemental Content

Support Center